SAN DIEGO–Sapient, a leader in multi-omics discovery, has announced a strategic partnership with Alamar Biosciences, Inc., a company renowned for its innovative ultra-sensitive and highly multiplexed immunoassay technologies. This collaboration marks a significant expansion of Sapient’s targeted proteomics services, now incorporating Alamar’s cutting-edge NULISA™ platform and ARGO® HT system to offer unparalleled high-sensitivity cytokine, chemokine, and neuroinflammatory mediator assays.
As a certified service provider for Alamar, Sapient will now feature the NULISAseq™ Inflammation Panel, capable of profiling over 250 cytokine and chemokine biomarkers, and the NULISAseq CNS Disease Panel, designed for profiling more than 120 low-abundance neurodegeneration and neuroinflammatory biomarkers. Furthermore, this partnership empowers Sapient to offer custom development of precision proteomics assays leveraging Alamar’s groundbreaking technologies. Sapient is also poised to work closely with Alamar to extend the availability of NULISAseq assays under stringent regulatory guidelines, including CAP/CLIA and GCLP, ensuring the highest standards for clinical applications.
The NULISA technology is revolutionizing precision proteomics by employing a unique sequential immunocomplex capture and release technique. This innovative approach amplifies the sensitivity of traditional proximity ligation assays by over a thousand-fold, reaching attomolar levels. This leap in sensitivity is crucial for detecting notoriously challenging low-abundance cytokines, chemokines, and neuroinflammatory mediators directly from biofluid samples. The integration of high-sensitivity NULISA assays is a strategic complement to Sapient’s existing mass spectrometry-based proteomics services. While mass spectrometry excels in broad proteome profiling for biomarker and drug target discovery, NULISA steps in to provide precise quantitation and validation of key proteins, especially those of low abundance that are often undetectable by mass spectrometry.
This partnership strengthens Sapient’s comprehensive multi-omics solutions, creating a robust platform to support the entire drug development lifecycle, from initial discovery phases through to critical clinical trials. By incorporating Alamar’s NULISA technology, Sapient is enhancing its ability to deliver deep, actionable insights to its pharmaceutical and biotech partners.
“Inflammatory profiling using NULISA technology is an exceptional addition to our established suite of proteomics, metabolomics, lipidomics, and RNAseq approaches. This expansion of our Sapient Partners network and technological capabilities allows us to thoroughly investigate the dynamic biomarkers of human health, disease progression, and drug responses for our clients, alongside identifying promising new drug targets,” stated Dr. Jonathan Usuka, PhD, MBA, Chief Executive Officer of Sapient. “Cytokines and chemokines are critical in modulating immune processes and are biologically significant across numerous disease areas. The major hurdle has been the difficulty in measuring these inflammatory mediators in human plasma due to their naturally low concentrations. Alamar’s NULISA technology overcomes this, enabling us to accurately detect subtle yet significant changes in the low-abundance proteome within plasma. By combining NULISA and mass spectrometry analyses, we achieve comprehensive coverage of the protein dynamic range in plasma, facilitating rapid validation and acceleration of discoveries.”
Dr. Yuling Luo, PhD, Founder, Chairman, and CEO of Alamar, commented, “We are thrilled to collaborate with Sapient as a certified service provider for our NULISAseq assays and as a trusted expert in developing tailored, custom assays for clients aiming to quantify key low-abundance proteins using our advanced technologies. We believe NULISA is setting a new benchmark in precision proteomics, and we recognize Sapient, with its CAP/CLIA accreditation, as the ideal partner to make these assays accessible to researchers focused on biomarker development for early disease detection and therapeutic advancements, thereby facilitating the integration of the Alamar platform into clinical trials.”
Dr. Mo Jain, MD, PhD, Founder and Chief Scientific Officer of Sapient, added, “Our team is enthusiastic about joining forces with Alamar to provide the best-in-class platform for high-sensitivity cytokine and chemokine measurements. This partnership not only enhances our mass spectrometry-based proteomics offerings but also significantly strengthens our capacity to deliver comprehensive multi-omics data and valuable insights to our clientele. We see Alamar as true sapient partners in innovation.”
About Sapient
Sapient is a pioneering force in biomarker discovery, leveraging state-of-the-art, high-throughput mass spectrometry and advanced biocomputational frameworks to deliver unmatched multi-omics data generation and analysis. By enabling comprehensive biomarker-phenotype mapping across extensive biosample collections, Sapient empowers biopharmaceutical innovators to propel precision drug development beyond the limitations of genomics. The company’s proprietary Human Biology Database, encompassing data from over 100,000 samples, accelerates drug target identification, biomarker discovery and validation, and translational insights across all stages of pharmaceutical development. Discover more at sapient.bio.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to advancing precision proteomics to enable earlier and more accurate disease detection. The company’s proprietary NULISA Platform, together with the ARGO® HT System, seamlessly integrates with the latest genomic advancements to achieve single-digit attomolar detection sensitivity, outperforming current protein detection technologies on the market. For additional information, please visit alamarbio.com.
Contacts
Media Contact:
Carla Nieser
Head of Marketing, Sapient
[email protected]
858.290.7010
